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Podoplanin (aggrus) is highly expressed in several types of cancers, including
malignant pleural mesothelioma (MPM). Previously, we developed a rat anti-
human podoplanin mAb, NZ-1, and a rat–human chimeric anti-human podoplanin
antibody, NZ-8, derived from NZ-1, which induced antibody-dependent cellular
cytotoxicity (ADCC) and complement-dependent cytotoxicity against podoplanin-
positive MPM cell lines. In this study, we showed the antitumor effect of NZ-1, NZ-
8, and NZ-12, a novel rat–human chimeric anti-human podoplanin antibody
derived from NZ-1, in an MPM orthotopic xenograft SCID mouse model. Treatment
with NZ-1 and rat NK (CD161a+) cells inhibited the growth of tumors and the pro-
duction of pleural effusion in NCI-H290/PDPN or NCI-H226 orthotopic xenograft
mouse models. NZ-8 and human natural killer (NK) (CD56+) cells also inhibited
tumor growth and pleural effusion in MPM orthotopic xenograft mice. Further-
more, NZ-12 induced potent ADCC mediated by human MNC, compared with either
NZ-1 or NZ-8. Antitumor effects were observed following treatment with NZ-12
and human NK (CD56+) cells in MPM orthotopic xenograft mice. In addition, com-
bined immunotherapy using the ADCC activity of NZ-12 mediated by human NK
(CD56+) cells with pemetrexed, led to enhanced antitumor effects in MPM ortho-
topic xenograft mice. These results strongly suggest that combination therapy
with podoplanin-targeting immunotherapy using both NZ-12 and pemetrexed
might provide an efficacious therapeutic strategy for the treatment of MPM.
E xpression of podoplanin (aggrus), a transmembrane sialo-mucin-like glycoprotein, has been detected in various nor-
mal tissues, including kidney podocytes, endothelium of
lymphatic vessels, and type I alveolar epithelium,(1–3) as well
as many types of cancers, including malignant brain tumor,
oral cancers, esophageal cancers, squamous carcinoma, testicu-
lar seminomas, bladder cancers, fibrosarcomas, and malignant
pleural mesothelioma (MPM).(4–9) Podoplanin, which binds to
the platelet aggregation-stimulating domain of PDPN–C-type
lectin-like receptor 2 in platelets, induces platelet aggregation,
resulting in cancer metastasis.(4,10) Furthermore, high expres-
sion of podoplanin in cancer-associated fibroblasts is associ-
ated with severe malignancy and poor prognosis in cancer
patients.(11–14) Therefore, it is expected that podoplanin will
become a target for cancer diagnosis and therapies.
Malignant pleural mesothelioma, which is mainly caused by
exposure to asbestos, develops in the pleural cavity with a high
likelihood of malignancy.(15) It is expected that the number of
MPM patients will increase from 2030 to 2040 in Asia, and
from 2010 to 2020 in Europe.(16,17) The standard therapy for
MPM involves a combination of surgical operations, radiation
therapy, and systemic chemotherapy. However, the prognosis
of MPM is very poor as MPM is one of the most progressive
cancers and frequently resists treatment.(18,19) Treatment with
pemetrexed, which is the only validated chemotherapy drug
for MPM, combined with cisplatin, is the standard chemother-
apy used in MPM patients; however, this combination therapy
often only prolongs progression-free survival by approximately
2.8 months, compared with treatment without pemetrexed.(20)
Thus, development of novel therapies for MPM is warranted
in order to improve the prognosis.
Immunotherapy using therapeutic antibodies against tumor-
associated antigens or antigenic peptides derived from peme-
trexed is a novel therapy for the treatment of various cancers,
including MPM.(21,22) Several therapeutic antibodies, includ-
ing trastuzumab and rituximab, are already being used in
clinical practice. Antibody-dependent cellular cytotoxicity
(ADCC) and complement-dependent cytotoxicity (CDC) are
critical mechanisms by which therapeutic antibodies provide
their antitumor effects.(23) Previously, we generated a rat
anti-human podoplanin mAb, NZ-1,(24–26) and a rat–human
chimeric anti-human podoplanin antibody, NZ-8, derived
from NZ-1.(9,27) These anti-podoplanin antibodies induce
potent ADCC and CDC activity against podoplanin-positive
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MPM cell lines in vitro, and had significant antitumor effects
in an MPM s.c. transplantation SCID mouse model. However,
whether the therapeutic effects of anti-podoplanin antibodies
in MPM orthotopic xenograft mice are similar to clinical pre-
sentation of MPM is still unknown. In the present study, we
investigated whether anti-human podoplanin antibodies NZ-1,
NZ-8, and NZ-12, a novel rat–human chimeric anti-human
podoplanin antibody derived from NZ-1, can induce antitu-
mor effects in an MPM orthotopic xenograft SCID mouse
model. Furthermore, we evaluated the antitumor effects of
combined treatment using anti-human podoplanin antibody-
based immunotherapy, and pemetrexed.
Materials and Methods
Cell lines. In this study, we used four human MPM cell lines.
NCI-H290, ACC-MESO-1, and ACC-MESO-4 were provided
by Dr. Yoshitaka Sekido (Division of Molecular Oncology,
Aichi Cancer Center Research Institute, Nagoya, Japan).(28)
NCI-H226 and Chinese hamster ovary (CHO) were purchased
from ATCC (Rockville, MD, USA). NCI-H290 cells were
transfected with appropriate amounts of pcDNA3/human podo-
planin or pcDNA3/mock plasmids, using Metafectene (Nippon
Genetics, Tokyo, Japan), according to the manufacturer’s
instructions. Stable transfectants (NCI-H290/PDPN and NCI-
H290/mock) were selected by culture in medium containing
0.5 mg/mL Geneticin (Invitrogen, Carlsbad, CA, USA). These
cells were maintained in RPMI-1640 medium supplemented
with 10% FBS (CRPMI-1640; Gibco, Grand Island, NY,
USA), 100 U/mL penicillin, and 100 lg/mL streptomycin
(Meiji Seika Kaisha, Tokyo, Japan) in 5% CO2 at 37°C.
Antibodies and reagents. Rat anti-human podoplanin mAb,
NZ-1, and rat–human chimeric anti-human podoplanin anti-
body, NZ-8, were developed as described previously.(24,27) For
the generation of rat–human chimera anti-human podoplanin
(NZ-12), the appropriate VH of a rat NZ-1 antibody and CH
of human IgG1 were subcloned into the pCAG-Neo (Wako
Pure Chemical Industries, Osaka, Japan), and VL of a rat NZ-
1 antibody and CL of human lambda chain were subcloned
into pCAG-Ble vectors (Wako Pure Chemical Industries).
Antibody expression vectors were transfected into CHO cells
using a Lipofectamine LTX kit (Life Technologies, Carlsbad,
CA, USA). Stable transfectants of CHO/NZ-12 were selected
by cultivating the transfectants in medium containing 1 mg/
mL Geneticin and 0.5 mg/mL Zeocin (Life Technologies).
The CHO/NZ-12 cells were cultivated in CHO-S-SFM II med-
ium (Life Technologies). The media containing NZ-12 were
centrifuged, and the obtained supernatant was applied to a col-
umn of protein G-Sepharose (Thermo Fisher Scientific, Rock-
ford, IL, USA). After extensive washing with PBS, the fusion
proteins were eluted using 0.1 M glycine and 0.15 M NaCl
(pH 2.8), and then neutralized with 1 M Tris (pH 10.0). The
antibodies were dialyzed against PBS. Expression and purity
of the proteins were confirmed by SDS-PAGE, using 5–20%
gradient gels (Wako Pure Chemical Industries). Rat IgG
(rIgG) was purchased from Southern Biotechnology (Birming-
ham, AL, USA). Human IgG (hIgG) was purchased from Cap-
pel (Cochranville, PA, USA). Pemetrexed was obtained from
Eli Lilly Japan (Kobe, Japan).
Animals. Five- to 6-week-old male SCID mice and 6-week-
old male Wistar rats were obtained from CLEA Japan (Osaka,
Japan) and maintained under specific pathogen-free conditions
throughout experiments. All animals were acclimatized for at
least 1 week before experiments. All experiments were carried
out in accordance with the guidelines of the Committee on Ani-
mal Care and Use of Tokushima University (Tokushima, Japan).
Flow cytometry. Expression of podoplanin was detected by
flow cytometry, as described previously.(9) Cells (5 9 105)
were washed with PBS and stained with NZ-1 (1 lg/mL) or
rIgG (1 lg/mL). After 30 min of incubation, cells were
washed with PBS and incubated for 30 min with FITC-conju-
gated goat F(ab’)2 fragment anti-rat IgG (H+L) antibody
(Beckman Coulter, Fullerton, CA, USA). Cells were washed
again and resuspended in PBS. A FACSCalibur flow cytometer
with CellQuest software (BD Biosciences, Franklin Lakes, NJ,
USA) was used for the analysis.
Preparation of effector cells. Effector cells were prepared as
previously described.(9,29,30) Rat splenocytes were harvested
from Wistar rat spleens. Spleens were homogenized in RPMI-
1640 and centrifuged. To deplete red blood cells, the cell
pellet was suspended in red blood cell lysis buffer (Sigma-
Aldrich, St. Louis, MO, USA). After washing and resuspension
in CRPMI-1640, splenocytes were used as effector cells. To
separate rat natural killer (NK) cells from rat splenocytes, a
magnetic cell-sorting system was used. Splenocytes were
incubated with FITC-conjugated anti-CD161a antibody (BD
Biosciences), followed by anti-FITC mAb-coupled super-para-
magnetic microbeads (Miltenyi Biotec, Auburn, CA, USA).
CD161a+ selection was carried out using an autoMACS (Mil-
tenyi Biotec). Isolated CD161a+ cells yielding purity ≥90%,
determined by flow cytometry, were used in experiments.
Human peripheral blood mononuclear cells (MNCs) were
obtained from leukocytes in lymphocyte separation medium
(Litton Bionetics, Kensington, MD, USA). Leukocytes were
separated from peripheral blood of healthy donors using a
Kubota KR-400 centrifuge with an RS-6600 rotor (Kubota,
Tokyo, Japan). CD56+ cells were purified from human MNCs,
which were treated with CD56 microbeads (Miltenyi Biotec),
and then cells were separated by autoMACS. The purity of
CD56+ cells was ≥90%. The human study was approved by
the ethics committee of University of Tokushima, and written
informed consent was obtained from all donors.
Antibody-dependent cellular cytotoxicity. Antibody-dependent
cellular cytotoxicity was determined using 51Cr release
assays.(9,29,31) Target cells were incubated with 51Cr-sodium
chromate (3.7 MBq) at 37°C for 1 h. After washing with
CRPMI-1640 three times, 51Cr-labeled target cells were placed
in triplicate in 96-well plates. Effector cells and anti-human
podoplanin antibody or control IgG were added to the plates.
After 6 h of incubation, 51Cr release of the supernatant from
each well (100 lL) was measured using a gamma counter
(PerkinElmer, Waltham, MA, USA). Percent of cytotoxicity
was calculated using the following formula: % specific
lysis = (E  S) / (M  S) 9 100, where E is the release in the
test sample, S is the spontaneous release, and M is the maximum
release.
Complement-dependent cytotoxicity. Complement-dependent
cytotoxicity was evaluated by 51Cr release assay, as described
previously.(9,32) Target cells were incubated with 51Cr-sodium
chromate (3.7 MBq) for 1 h at 37°C. Following this, cells were
washed in CRPMI-1640. The 51Cr-labeled cells were incubated
with baby rabbit complement (dilution of 1:4) (Cedarlane,
Burlington, VT, Canada) and NZ-12 (1 lg/mL) or control hIgG
(1 lg/mL) for 6 h in 96-well plates. After incubation, the super-
natant, including 51Cr, was measured using a gamma counter.
Percent cytotoxicity was calculated as described above.
Animal experiments. SCID mice were injected into the tho-
racic cavity with NCI-H290/PDPN (1.0 9 106 cells) or NCI-
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H226 (1.0 9 106 cells) on day 0. Intrathoracic administration
or i.p. injection of anti-human podoplanin antibody or control
IgG began on day 0, and continued twice a week for 2–
3 weeks. Rat CD161a+ cells (1.0 9 106 cells), human CD56+
cells (1.0 9 106 cells), or control normal saline were injected
into the thoracic cavity from day 3, and continued weekly for
2–3 weeks. SCID mice of the pemetrexed combination group
were treated with pemetrexed (100 mg/kg, i.p.) on days 4, 5,
6, 11, 12, and 13, as described previously.(33) Three weeks
(NCI-H290/PDPN) or 9 weeks (NCI-H226) after tumor cell
inoculation, the mice were killed, thoracic tumors were
weighed, and the volume of pleural effusion was measured
using a 1-mL syringe.
Statistical analyses. The statistical significance of differences
in in vitro and in vivo data was analyzed using standard Stu-
dent’s t-test and one-way ANOVA. P-values < 0.05 were consid-
ered significant in all experiments.
Results
Rat anti-human podoplanin antibody NZ-1 induces ADCC
against podoplanin-transfected MPM cell lines. First, we con-
firmed that NZ-1 induces ADCC against NCI-H290/PDPN in
target cells. NCI-H290, one of the podoplanin-negative MPM
cell lines, develops thoracic tumors and pleural effusion in an
orthotropic xenograft SCID mouse model.(34) We generated
NCI-H290/PDPN to transfect pcDNA3/podoplanin into NCI-
H290. As shown in Fig. 1(a), podoplanin expression in
NCI-H290/PDPN was determined by flow cytometry. Using
NCI-H290/PDPN as target cells, we could detect ADCC
induced by NZ-1 with rat splenocytes (Fig. 1b). Figure 1(c)
shows that effector/target cell-dependent and dose-dependent
ADCC activities against NCI-H290/PDPN were also induced
by NZ-1. Moreover, NZ-1 showed significant ADCC activity
against NCI-H290/PDPN and NCI-H226 when rat NK cells
were used as target cells (Fig. 1d).
Antitumor activity of NZ-1 in MPM orthotopic xenograft
model. Previously, we reported that injection of both NZ-1 and
rat NK cells inhibited the growth of podoplanin-positive MPM
cells inoculated s.c. in SCID mice.(9) To determine whether
NZ-1 also induced an antitumor effect in an orthotopic xeno-
graft model, we first evaluated the effects of local administra-
tion of NZ-1 in NCI-H290/PDPN orthotopic xenograft mice.
For 2 weeks, NZ-1 or control IgG was injected into the tho-
racic cavity twice a week, and rat NK (CD161a+) cells or PBS
was injected into the thoracic cavity once a week. Three weeks
after tumor cell inoculation, tumor growth and production of
pleural effusion was almost entirely inhibited in both the NZ-1
and rat NK cells treatment groups (Fig. 2). In contrast, treat-
ment with NZ-1 alone did not produce an antitumor effect in
our model. Next, we investigated whether systemic treatment
of NZ-1 induced antitumor effects in the orthotopic xenograft
SCID mouse model. For 3 weeks, NZ-1 or rIgG was injected
i.p. twice a week, and rat NK cells or PBS were injected once
a week into the thoracic cavity. In both NCI-H290/PDPN- and
NCI-H226-inoculated mice, systemic administration of NZ-1
with rat NK cells significantly inhibited growth of intrathoracic
tumors and production of pleural effusion, compared with
either NZ-1 or rat NK cell treatment alone (Fig. 3).
Antitumor activity of NZ-8 in MPM orthotopic xenograft model.
We previously reported that NZ-8 induced ADCC activity
mediated by human NK cells.(9) To evaluate the antitumor
effects of NZ-8 combined with human NK cells in an MPM
orthotopic xenograft model, we used the NCI-H290/PDPN
orthotopic xenograft mouse model. As shown in Figure 4(a),
ADCC activity against NCI-H290/PDPN was observed follow-
ing treatment with NZ-8 and human MNC. Injection of NZ-8
(i.p.) twice a week and human NK (CD56+) cells injected into
the thoracic cavity weekly for 2 weeks significantly inhibited
tumor weight and pleural effusion production, compared with
NZ-8 or human NK cells alone (Fig. 4b).
In vitro and in vivo antitumor effects of NZ-12. Given that
NZ-1 and NZ-8 induced antitumor effects in MPM in an ortho-
topic xenograft model, we generated a novel rat–human chi-
meric anti-human podoplanin antibody, NZ-12, derived from
NZ-1, in order to establish a more potent target therapy for
podoplanin. As shown in Figure 5(a), NZ-12 induced a signifi-
cant level of ADCC, mediated by human MNC, against
Fig. 1. Antibody-dependent cellular cytotoxicity
(ADCC) activity of rat anti–human podoplanin
antibody NZ-1 against NCI-H290/PDPN in vitro. (a)
Expression of podoplanin was detected by FACS
analysis. (b) ADCC activity of NZ-1 using rat
splenocytes against NCI-H290/PDPN or NCI-H290/
Mock was evaluated by 6-h 51Cr release assay in the
presence of antibody (1 lg/mL; effector/target [E/T]
ratio 100). (c) E/T ratio-dependent and antibody
dose-dependent effects of ADCC against NCI-H290/
PDPN mediated by NZ-1 with rat splenocytes are
shown by 51Cr release assay. (d) Rat natural killer
(NK) (CD161a+) cells were isolated from rat
splenocytes. ADCC activity of NZ-1 (1 lg/mL)
mediated by NK (CD161a+) cells was evaluated by 6-
h 51Cr release assay at an E/T ratio of 10. **P < 0.01
versus control (values represent mean  SE). rIgG,
rat IgG.
© 2016 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd
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podoplanin-positive MPM cells. The ADCC activity induced
by NZ-12 was significantly higher than that of NZ1 or NZ-8.
NZ-12 also induced CDC activity against podoplanin-positive
MPM cells (Fig. 5b). Moreover, ADCC activity of NZ-12 was
mediated by human NK (CD56+) cells (Fig. 5c). In the NCI-
H290/PDPN orthotopic xenograft SCID mouse model, tumor
weight and production of pleural effusion was significantly
inhibited by 2 weeks of injections of NZ-12 (i.p.), given twice
a week, co-administered with injections of human NK
(CD56+) cells into the thoracic cavity, given once a week
(Fig. 5d,e). By contrast, treatment with NZ-12 alone did not
inhibit tumor growth.
Effect of combination treatment of NZ-12 and peme-
trexed. Our result suggested that combined treatment with NZ-
12 and human NK cells inhibited tumor growth in an MPM
orthotropic model. Additionally, we further revealed the effi-
cacy of NZ-12 against MPM using combined treatment of NZ-
12 and pemetrexed in an MPM SCID mouse model. As shown
in Figure 6(a), expression of podoplanin in NCI-H290/PDPN
was unchanged following 72 h of incubation with pemetrexed
(0.1 lM). In contrast, the same treatment condition of peme-
trexed inhibited the proliferation of NCI-H290/PDPN in vitro
(data not shown). Furthermore, treatment with pemetrexed in
target cells did not inhibit ADCC activity induced by NZ-12
with human MNC (Fig. 6b). Using the orthotopic xenograft
SCID mouse model, injection of NZ-12 (i.p.), human NK
(CD56+) cells injected into thoracic cavity, and pemetrexed
(i.p.) significantly reduced intrathoracic tumor growth and pro-
duction of pleural effusion, compared with the immunotherapy
of NZ-12 (NZ-12 with human NK cells) or pemetrexed alone
(Fig. 6c).
Discussion
In the present study, we have shown that anti-human podopla-
nin antibodies NZ-1, NZ-8, and NZ-12 possess therapeutic
antitumor effects in an MPM orthotopic xenograft SCID
mouse model. Furthermore, NZ-12 induced more ADCC
activity than NZ-1 or NZ-8. In addition, we have shown that
combination treatment of NZ-12 and pemetrexed produced sig-
nificantly greater antitumor activity than each single therapy.
These findings suggested that NZ-12 is an effective antibody
against MPM.
We previously established a human MPM orthotopic xeno-
graft SCID mouse model, in which MPM cells were inoculated
into the thoracic cavity.(33,35) Several weeks after inoculation,
the mice died due to increased size of thoracic tumors and pro-
duction of bloody pleural effusion inside the thoracic cavity.
As this disease state is similar to that of human MPM patients,
this model could be used to evaluate the efficacy of therapeutic
treatments of MPM.(34,36) Although our previous study only
showed the antitumor effects of an anti-human podoplanin
antibody given with NK cells in an MPM s.c. xenograft
model,(9) in this study, administration of anti-human podopla-
nin antibodies NZ-1, NZ-8, and NZ-12 with NK cells reduced
growth of thoracic tumors and production of pleural effusion
in an MPM orthotopic xenograft model. By contrast, no
antitumor effects were observed following injection of the
anti-human podoplanin antibody alone in this experimental
condition. Treatment of NK cells with control IgG partly
inhibited the tumor growth because of antitumor activity of
NK cells alone. Production of pleural effusion closely depends
on the tumor size above a certain level in MPM orthotopic
xenograft model. Therefore, pleural effusion was completely
inhibited in Figure 2. However, anti-human podoplanin anti-
body with NK cells significantly inhibited tumor weight com-
pared with NK cells alone. These results indicate that the
antitumor effects of anti-human podoplanin antibodies in the
MPM orthotopic xenograft mouse model are mediated by NK
cell-mediated ADCC. Furthermore, cancer progression was
reduced not only by intrathoracic injection of the anti-human
podoplanin antibody, but also by i.p. injection. As the drug
injection into the thoracic cavity produced several side-effects,
including pneumothorax, inflammation, and infection, systemic
administration is preferable in clinical practice. Therefore, in
the current study, it appears that systemic treatment with anti-
Fig. 2. Antitumor effects of NZ-1 injected into the
thoracic cavity in an NCI-H290/PDPN malignant
pleural mesothelioma orthotopic xenograft model.
SCID mice (n = 5) were injected into the thoracic
cavity with 1.0 9 106 NCI-H290/PDPN cells. NZ-1
(100 lg) or rat IgG (rIgG; 100 lg) intrathoracic
injection began on day 0, and continued twice a
week for 2 weeks. Rat NK (CD161a+) cells (1.0 9 106
cells) or control normal saline intrathoracic
injections continued weekly for 2 weeks. Three
weeks after tumor cell inoculation, the mice were
killed, and the weight of thoracic tumors (white
arrows) and volume of pleural effusion were
measured. **P < 0.01 (values represent mean  SE).
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human podoplanin antibodies would be beneficial in podopla-
nin-positive MPM patients.
We have shown that NZ-12, a novel rat–human chimeric
anti-human podoplanin antibody generated from NZ-1, with
human NK cells induced antitumor effects against MPM
in vitro and in vivo. The ADCC activity of NZ-12 mediated by
human NK cells was much higher than that of NZ-1 or NZ-8.
In our previous study, NZ-1 could only induce ADCC activity
by rat NK cells because NZ-1 was a rat anti-human podoplanin
antibody.(9) However, NZ-8, another rat-human chimeric anti-
human podoplanin antibody generated from NZ-1, could
induce ADCC activity by human NK cells as effector cells.
The reason why ADCC activity of NZ-12 was significantly
higher than that of NZ-8 is still unknown. However, it may be
related to differences in the development method of NZ-12
and NZ-8. In development of the human chimeric antibody,
the kappa chain was generally used as the antibody light chain,
and NZ-8 was also established using the kappa chain. In con-
trast, because NZ-1 has a lambda chain of the rat antibody,
NZ-12 was also generated using the human lambda chain.
Therefore, it might be considered that the potent ADCC activ-
ity of NZ-12, compared with NZ-8, was caused by differences
Fig. 3. Antitumor effects of NZ-1 i.p. injection in a
malignant pleural mesothelioma orthotopic
xenograft model. SCID mice (n = 5) were injected
into the thoracic cavity with NCI-H290/PDPN (a) or
NCI-H226 (b) (1.0 9 106 cells). Intraperitoneal
injection of NZ-1 (100 lg) or rat IgG (rIgG; 100 lg)
began on day 0, and continued twice a week for
3 weeks. Intrathoracic injection of rat CD161a+ cells
(1.0 9 106 cells) or control normal saline began on
day 3, and continued weekly for 3 weeks. Three
weeks (NCI-H290/PDPN) or 9 weeks (NCI-H226) after
tumor cell inoculation, mice were killed. *P < 0.05,
**P < 0.01 (values represent mean  SE).
Fig. 4. Antitumor activity of rat–human chimeric
anti-human podoplanin antibody NZ-8 in an NCI-
H290/PDPN malignant pleural mesothelioma
orthotopic xenograft model. (a) Antibody-
dependent cellular cytotoxic activity against NCI-
H290/PDPN was determined with 6-h 51Cr release
assay (effector/target ratio 100) in the presence of
human IgG (hIgG; 1 lg/mL), NZ-1 (1 lg/mL), or NZ-8
(1 lg/mL), with human peripheral blood
mononuclear cells (MNC). (b) NCI-H290/PDPN
(1.0 9 106 cells) was inoculated into the thoracic
cavity on day 0 (n = 5). NZ-8 (100 lg) or hIgG
(100 lg) injection (i.p.) also began on day 0, and
continued twice a week for 2 weeks. Human
natural killer (NK) (CD56+) cells (1.0 9 106 cells) or
control normal saline were injected into the
thoracic cavity from day 3, and continued weekly
for 2 weeks. Mice were killed 3 weeks after tumor
cell inoculation. *P < 0.05, **P < 0.01 (values
represent mean  SE).
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Fig. 5. Antitumor effects of novel rat–human
chimeric anti-human podoplanin antibody NZ-12
in vitro and in vivo. (a) Antibody-dependent
cellular cytotoxicity induced by human peripheral
blood mononuclear cells (MNC) against malignant
pleural mesothelioma cell lines ACC-MESO-1, ACC-
MESO-4, NCI-H226, and NCI-H290/PDPN, was
evaluated by 6-h 51Cr release assay (effector/target
ratio 100) in the presence of human IgG (hIgG;
1 lg/mL), NZ-1 (1 lg/mL), NZ-8 (1 lg/mL), and NZ-12
(1 lg/mL), with human MNC. (b) Complement-
dependent cytotoxic activity was indicated by 6-h
51Cr release assay in the presence of NZ-12 (1 lg/
mL) or hIgG with baby rabbit complement (1:4
dilution). (c) Human natural killer (NK) (CD56+) cells
were isolated from human MNC. Antibody-
dependent cellular cytotoxic activity of NZ-12 (1 lg/
mL) mediated by human NK (CD56+) cells was
evaluated by 6-h 51Cr release assay at an effector/
target ratio of 5, 10, and 25. (d, e) SCID mice
(n = 5) were injected with NCI-H290/PDPN
(1.0 9 106 cells) into the thoracic cavity. NZ-12
(100 lg) or hIgG (100 lg) injection (i.p.) was
continued twice a week for 2 weeks. Human NK
(CD56+) cells (1.0 9 105 cells) were injected into the
thoracic cavity weekly for 2 weeks. Three weeks
after tumor cell inoculation, the mice were killed
and the weight of thoracic tumors (white arrows)
and volume of pleural effusion were measured.
*P < 0.05, **P < 0.01 (values represent mean  SE).
Fig. 6. Combinatory effects of treatment for
malignant pleural mesothelioma with NZ-12-based
immunotherapy and pemetrexed in vivo. (a) NCI-
H290/PDPN was incubated with pemetrexed
(0.1 lM). After 72 h of incubation, expression of
podoplanin was evaluated by FACS analysis. (b)
Antibody-dependent cellular cytotoxic activity of
NZ-12 (1 lg/mL) against NCI-H290/PDPN mediated
by human peripheral blood mononuclear cells
(MNC) was evaluated by 6-h 51Cr release assay
(effector/target ratio 100) in the presence or
absence of pemetrexed (0.1 lM). NCI-H290/PDPN
treated with pemetrexed (0.1 lM) for 72 h was also
used in target cells. (c) SCID mice (n = 5) were
injected with NCI-H290/PDPN (1.0 9 106 cells) into
the thoracic cavity. NZ-12 (100 lg) or human IgG
(hIgG; 100 lg) was injected i.p. twice a week for
2 weeks. Human natural killer (NK) (CD56+) cells
(1.0 9 105 cells) or normal saline was injected into
the thoracic cavity weekly for 2 weeks. Pemetrexed
(100 mg/kg, i.p.) was given on days 4, 5, 6, 11, 12,
and 13. *P < 0.05, **P < 0.01 (values represent
mean  SE). N.S., not significant.
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in the binding affinity of NZ-12 against podoplanin due to the
development method. In addition, CDC activity in ACC-
MESO-1 and ADCC activity in ACC-MESO-4 were relatively
lower compared to other cell lines. We previously showed that
ACC-MESO-1, ACC-MESO-4, and NCI-H226 express high
levels of podoplanin.(9) Therefore, the expression level of
podoplanin was probably not related. We speculated that the
sensitivity of several cell lines against the cytotoxic mecha-
nisms induced by NK cells or complements were related to
differences in ADCC and CDC activity.
Pemetrexed combined with cisplatin is the standard
chemotherapy used in the treatment of MPM patients. How-
ever, this combined treatment often only prolongs survival in
patients by approximately 2.8 months, compared with cisplatin
treatment alone.(20) Therefore, development of novel therapeu-
tic strategies in combination with pemetrexed are needed to
improve therapeutic treatments for MPM. In this study, pro-
longed treatment with pemetrexed did not change the expres-
sion level of podoplanin in MPM cells, suggesting that ADCC
activity of NZ-12 against MPM was not inhibited by peme-
trexed in vitro. In addition, the combined immunotherapy of
NZ-12, mediated by human NK cells, with pemetrexed injec-
tion enhanced antitumor effects by both induction of ADCC
activity and antifolate action in an MPM orthotopic xenograft
model. Although many anticancer chemotherapy drugs sup-
press immune function due to myelosuppression, several
chemotherapy drugs, including gemcitabine, combine with the
effects of immunotherapy to modulate immune function.(37,38)
Pemetrexed, which is an antifolate antimetabolite agent, is
likely to induce myelosuppression. Nevertheless, it is reported
that antifolate agents enhanced the production of interleukin-2
and interleukin-12.(39) The detailed mechanism is still unclear,
but our results suggest that treatment with both NZ-12-
mediated immunotherapy and pemetrexed induces combined
effects against intrathoracic MPM. These are likely additive
effects, as pemetrexed had no effect on the expression of
podoplanin or ADCC activity of NZ-12 mediated by human
NK cells.
In conclusion, we found that anti-human podoplanin antibod-
ies possess ADCC activity-induced antitumor effects in an
MPM orthotopic xenograft model. Furthermore, combined
treatment of NZ-12, which induced potent ADCC activity
mediated by human NK cells, and pemetrexed produced
enhanced antitumor effects in an MPM orthotopic xenograft
model. These findings suggest that combination therapy using
both NZ-12 podoplanin-targeting immunotherapy and peme-
trexed could provide a promising therapeutic strategy in the
treatment of MPM.
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